Abnormal NF-κB function characterizes human type 1 diabetes dendritic cells and monocytes

Journal of Immunology

Volumn 180, Issue 5, 2008, Pages 3166-3175

  Mollah, Zia U A ^a   Pai, Saparna ^a   Moore, Craig ^a   O'Sullivan, Brendan J ^a   Harrison, Matthew J ^a   Peng, Judy ^a   Phillips, Karen ^a   Prins, Johannes B ^a   Cardinal, John ^b   Thomas, Ranjeny ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD40 ANTIGEN; CELL NUCLEUS DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN P50; PROTEIN TYROSINE PHOSPHATASE SHP 1; STIBOGLUCONATE SODIUM; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CELL ISOLATION; CELLULAR IMMUNITY; CHILD; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DIABETIC PATIENT; FEMALE; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SCHOOL CHILD; ANTIGEN PRESENTATION; CELL CULTURE; DRUG ANTAGONISM; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION;

ADOLESCENT; ADULT; AGED; ANTIGEN PRESENTATION; CELL DIFFERENTIATION; CELLS, CULTURED; CHILD; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MONOCYTES; NF-KAPPA B; T-LYMPHOCYTE SUBSETS;

EID: 49149097651     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.5.3166     Document Type: Article

References (67)

1. Thomas, R., K. P. A. MacDonald, A. R. Pettit, L. L. Cavanagh, J. Padmanabha, and S. Zehntner. 1999. Dendritic cells and the pathogenesis of rheumatoid arthritis. J. Leukocyte Biol. 66: 286-292.
2. Summers, K. L., M. T. Behme, J. L. Mahon, and B. Singh. 2003. Characterization of dendritic cells in humans with type 1 diabetes. Ann. NY Acad. Sci. 1005: 226-229.
3. Schnare, M., G. M. Barton, A. C. Holt, K. Takeda, S. Akira, and R. Medzhitov. 2001. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol. 2: 947-950.
4. O'Sullivan, B., A. G. Thompson, and R. Thomas. 2007. NF-κB as a therapeutic target in autoimmune disease. Curr. Opin. Ther. Targets 11: 111-122.
5. Basak, S., H. Kim, J. D. Kearns, V. Tergaonkar, E. O'Dea, S. L. Werner, C. A. Benedict, C. F. Ware, G. Ghosh, I. M. Verma, and A. Hoffmann. 2007. A fourth IκB protein within the NF-κB signaling module. Cell 128: 369-381.
6. O'Sullivan, B. J., and R. Thomas. 2002. CD40 Ligation conditions dendritic cell antigen-presenting function through sustained activation of NF-κB. J. Immunol. 168: 5491-5498.
7. Chen, Z. J. 2005. Ubiquitin signalling in the NF-κB pathway. Nat. Cell. Biol. 7: 758-765.
8. Pettit, A. R., C. Quinn, K. P. MacDonald, L. L. Cavanagh, G. Thomas, W. Townsend, M. Handel, and R. Thomas. 1997. Nuclear localization of RelB is associated with effective antigen-presenting cell function. J. Immunol. 159: 3681-3691.
9. + cells are found in normal lymphoid organs and in peripheral tissue in the context of inflammation, but not under normal resting conditions. Immunol. Cell. Biol. 80: 164-169.
10. O'Sullivan, B. J., K. P. MacDonald, A. R. Pettit, and R. Thomas. 2000. RelB nuclear translocation regulates B cell MHC molecule, CD40 expression, and antigen-presenting cell function. Proc. Natl. Acad. Sci. USA 97: 11421-11426.
11. Jansen, A., M. van Hagen, and H. A. Drexhage. 1995. Defective maturation and function of antigen-presenting cells in type 1 diabetes. Lancet 345: 491-492.
12. Skarsvik, S., M. Tiittanen, A. Lindstrom, R. Casas, J. Ludvigsson, and O. Vaarala. 2004. Poor in vitro maturation and pro-inflammatory cytokine response of dendritic cells in children at genetic risk of type 1 diabetes. Scand. J. Immunol. 60: 647-652.
13. Dosch, H., R. K. Cheung, W. Karges, M. Pietropaolo, and D. J. Becker. 1999. Persistent T cell anergy in human type 1 diabetes. J. Immunol. 163: 6933-6940.
14. O'Sullivan, B., and R. Thomas. 2003. CD40 and dendritic cell function. Crit. Rev. Immunol. 23: 83-107.
15. Pathak, M. K., and T. Yi. 2001. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J. Immunol. 167: 3391-3397.
16. Zarnegar, B., J. Q. He, G. Oganesyan, A. Hoffmann, D. Baltimore, and G. Cheng. 2004. Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-κB activation pathways. Proc. Natl. Acad. Sci. USA 101: 8108-8113.
17. Mordmuller, B., D. Krappmann, M. Esen, E. Wegener, and C. Scheidereit. 2003. Lymphotoxin and lipopolysaccharide induce NF-κB-p52 generation by a cotranslational mechanism. EMBO Rep. 4: 82-87.
18. Bierhaus, A., S. Schiekofer, M. Schwaninger, M. Andrassy, P. M. Humpert, J. Chen, M. Hong, T. Luther, T. Henle, I. Kloting, et al. 2001. Diabetes-associated sustained activation of the transcription factor nuclear factor-κB. Diabetes 50: 2792-2808.
19. Bren, G. D., N. J. Solan, H. Miyoshi, K. N. Pennington, L. J. Pobst, and C. V. Paya. 2001. Transcription of the RelB gene is regulated by NF-κB. Oncogene 20: 7722-7733.
20. Arrighi, J. F., M. Rebsamen, F. Rousset, V. Kindler, and C. Hauser. 2001. A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-α, and contact sensitizers. J. Immunol. 166: 3837-3845.
21. Moore, F., S. Buonocore, E. Aksoy, N. Ouled-Haddou, S. Goriely, E. Lazarova, F. Paulart, C. Heirman, E. Vaeremans, K. Thielemans, et al. 2007. An alternative pathway of NF-κB activation results in maturation and T cell priming activity of dendritic cells overexpressing a mutated IκBα. J. Immunol. 178: 1301-1311.
22. Ouaaz, F., J. Arron, Y. Zheng, Y. Choi, and A. A. Beg. 2002. Dendritic cell development and survival require distinct NF-κB subunits. Immunity 16: 257-270.
23. Martin, E., B. O'Sullivan, P. Low, and R. Thomas. 2003. Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity 18: 155-167.
24. Platzer, B., A. Jorgl, S. Taschner, B. Hocher, and H. Strobl. 2004. RelB regulates human dendritic cell subset development by promoting monocyte intermediates. Blood 104: 3655-3663.
25. Neznanov, N., L. Neznanova, R. V. Kondratov, D. M. O'Rourke, A. Ullrich, and A. V. Gudkov. 2004. The ability of protein tyrosine phosphatase SHP-1 to suppress NF́B can be inhibited by dominant negative mutant of SIRPα. DNA Cell. Biol. 23: 175-182.
26. Poole, A. W., and M. L. Jones. 2005. A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail. Cell. Signal. 17: 1323-1332.
27. Tsui, H. W., K. A. Siminovitch, L. de Souza, and F. W. Tsui. 1993. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat. Genet. 4: 124-129.
28. Dubois, M. J., S. Bergeron, H. J. Kim, L. Dombrowski, M. Perreault, B. Fournes, R. Faure, M. Olivier, N. Beauchemin, G. I. Shulman, et al. 2006. The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis. Nat. Med. 12: 549-556.
29. Khaled, A. R., E. J. Butfiloski, E. S. Sobel, and J. Schiffenbauer. 1998. Functional consequences of the SHP-1 defect in motheaten viable mice: role of NF-κB. Cell. Immunol. 185: 49-58.
30. Massa, P. T., and C. Wu. 1998. Increased inducible activation of NF-κB and responsive genes in astrocytes deficient in the protein tyrosine phosphatase SHP-1. J Interferon Cytokine Res. 18: 499-507.
31. Thomas, R. 2005. The TRAF6-NF-κB signaling pathway in autoimmunity: not just inflammation. Arthritis Res. Ther. 7: 170-173.
32. Xie, J., J. Qian, S. Wang, M. E. Freeman, 3rd, J. Epstein, and Q. Yi. 2003. Novel and detrimental effects of lipopolysaccharide on in vitro generation of immature dendritic cells: involvement of mitogen-activated protein kinase p38. J. Immunol. 171: 4792-4800.
33. Weih, F., G. Warr, H. Yang, and R. Bravo. 1997. Multifocal defects in immune responses in RelB-deficient mice. J. Immunol. 158: 5211-5218.
34. Hoffmann, A., and D. Baltimore. 2006. Circuitry of nuclear factor κB signaling. Immunol. Rev. 210: 171-186.
35. Marienfeld, R., M. J. May, I. Berberich, E. Serfling, S. Ghosh, and M. Neumann. 2003. RelB forms transcriptionally inactive complexes with RelA/p65. J. Biol. Chem. 278: 19852-19860.
36. Jacque, E., T. Tchenio, G. Piton, P. H. Romeo, and V. Baud. 2005. RelA repression of RelB activity induces selective gene activation downstream of TNF receptors. Proc. Natl. Acad. Sci. USA 102: 14635-14640.
37. Akiyama, T., S. Maeda, S. Yamane, K. Ogino, M. Kasai, F. Kajiura, M. Matsumoto, and J. Inoue. 2005. Dependence of self-tolerance on TRAF6-directed development of thymic stroma. Science 308: 248-251.
38. + T cells reveals an essential requirement for nuclear factor κB in regulating mature T cell survival and in vivo function. J. Exp. Med. 197: 861-874.
39. Jansen, A., F. Delarch-Homo, H. Hooijkaas, P. J. Leenen, M. Dardenne, and H. A. Drexhage. 1994. Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulitis and β-cell destruction in NOD mice. Diabetes 43: 667-675.
40. Takahashi, K., M. C. Honeyman, and L. C. Harrison. 1998. Impaired yield, phenotype, and function of monocyte-derived dendritic cells in humans at risk for insulin-dependent diabetes. J. Immunol. 161: 2629-2635.
41. Cella, M., D. Scheidegger, K. Palmer Lehmann, P. Lane, A. Lanzavecchia, and G. Alber. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184: 747-752.
42. Caux, C., C. Massacrier, B. Vanbervliet, B. Dubois, C. van Kooten, I. Durand, and J. Banchereau. 1994. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 180: 1263-1272.
43. Saccani, S., S. Pantano, and G. Natoli. 2003. Modulation of NF-κB activity by exchange of dimers. Mol. Cell. 11: 1563-1574.
44. Tone, M., Y. Tone, J. M. Babik, C. Y. Lin, and H. Waldmann. 2002. The role of Sp1 and NF-κB in regulating CD40 gene expression. J. Biol. Chem. 277: 8890-8897.
45. Dejardin, E., V. Deregowski, R. Greimers, Z. Cai, S. Chouaib, M.-P. Merville, and V. Bours. 1998. Regulation of major histocompatibility complex class I expression by NF-κB-related proteins in breast cancer cells. Oncogene 16: 3299-3307.
46. Vuckovic, S., G. Withers, M. Harris, D. Khalil, D. Gardiner, I. Flesch, S. Tepes, R. Greer, D. Cowley, A. Cotterill, and D. N. Hart. 2007. Decreased blood dendritic cell counts in type 1 diabetic children. Clin. Immunol. 123: 281-288.
47. Burkly, L., C. Hession, L. Ogata, C. Reilly, L. A. Marconi, D. Olson, R. Tizard, R. Cate, and D. Lo. 1995. Expression of relB is required for the development of thymic medulla and dendritic cells. Nature 373: 531-536.
48. Weih, F., D. Carrasco, S. K. Durham, D. S. Barton, C. A. Rizzo, R. P. Ryseck, S. A. Lira, and R. Bravo. 1995. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NFκB/Rel family. Cell 80: 331-340.
49. Kumanogoh, A., X. Wang, I. Lee, C. Watanabe, M. Kamanaka, W. Shi, K. Yoshida, T. Sato, S. Habu, M. Itoh, et al. 2001. Increased T cell autoreactivity in the absence of CD40-CD40 ligand interactions: a role of CD40 in regulatory T cell development. J. Immunol. 166: 353-360.
50. Xia, Y., M. E. Pauza, L. Feng, and D. Lo. 1997. RelB regulation of chemokine expression modulates local inflammation. Am. J. Pathol. 151: 375-387.
51. Naik, S. H., D. Metcalf, A. van Nieuwenhuijze, I. Wicks, L. Wu, M. O'Keeffe, and K. Shortman. 2006. Intrasplenic steady-state dendritic cell precursors that are distinct from monocytes. Nat. Immunol. 7: 663-671.
52. Hypponen, E., E. Laara, A. Reunanen, M. R. Jarvelin, and S. M. Virtanen. 2001. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 358: 1500-1503.
53. Akerblom, H. K., O. Vaarala, H. Hyoty, J. Ilonen, and M. Knip. 2002. Environmental factors in the etiology of type 1 diabetes. Am. J. Med. Genet. 115: 18-29.
54. Norris, J. M. 2001. Can the sunshine vitamin shed light on type 1 diabetes? Lancet 358: 1476-1478.
55. Pozzilli, P., S. Manfrini, A. Crino, A. Picardi, C. Leomanni, V. Cherubini, L. Valente, M. Khazrai, and N. Visalli. 2005. Low levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes. Horm. Metab. Res. 37: 680-683.
56. 2007. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447: 661-678.
57. Hayashi, T., and D. Faustman. 1999. NOD mice are defective in proteasome production and activation of NF-κB. Mol. Cell. Biol. 19: 8646-8659.
58. Weaver, D. J., Jr., B. Poligone, T. Bui, U. M. Abdel-Motal, A. S. Baldwin, Jr., and R. Tisch. 2001. Dendritic cells from nonobese diabetic mice exhibit a defect in NF-κB regulation due to a hyperactive IκB kinase. J. Immunol. 167: 1461-1468.
59. Wheat, W., R. Kupfer, D. G. Gutches, G. R. Rayat, J. Beilke, R. I. Scheinman, and D. R. Wegmann. 2004. Increased NF-κB activity in B cells and bone marrow-derived dendritic cells from NOD mice. Eur. J. Immunol. 34: 1395-1404.
60. Paling, N. R., and M. J. Welham. 2005. Tyrosine phosphatase SHP-1 acts at different stages of development to regulate hematopoiesis. Blood 105: 4290-4297.
61. Stefanova, I., B. Hemmer, M. Vergelli, R. Martin, W. E. Biddison, and R. N. Germain. 2003. TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat. Immunol. 4: 248-254.
62. Carter, J. D., B. G. Neel, and U. Lorenz. 1999. The tyrosine phosphatase SHP-1 influences thymocyte selection by setting TCR signaling thresholds. Int. Immunol. 11: 1999-2014.
63. Piao, X., R. Paulson, P. van der Geer, T. Pawson, and A. Bernstein. 1996. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. Proc. Natl. Acad. Sci. USA 93: 14665-14669.
64. + T-cells from patients with type 1 diabetes. Diabetes 54: 92-99.
65. Arif, S., T. I. Tree, T. P. Astill, J. M. Tremble, A. J. Bishop, C. M. Dayan, B. O. Roep, and M. Peakman. 2004. Autoreactive T cell responses show proin-flammatory polarization in diabetes but a regulatory phenotype in health. J. Clin. Invest. 113: 451-463.
66. Eibl, N., M. Spatz, G. F. Fischer, W. R. Mayr, A. Samstag, H. M. Wolf, G. Schernthaner, and M. M. Eibl. 2002. Impaired primary immune response in type-1 diabetes: results from a controlled vaccination study. Clin. Immunol. 103: 249-259.
67. Keymeulen, B., E. Vandemeulebroucke, A. G. Ziegler, C. Mathieu, L. Kaufman, G. Hale, F. Gorus, M. Goldman, M. Walter, S. Candon, et al. 2005. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352: 2598-2608.